Yung Hao Pung, MD
Pediatric Allergy/Immunology · Rockville, MDNPI 1396733473
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Optinose US, Inc. at 29.6% of the total. Reporting peaked in 2019 at $4,348 and has fallen 73.1% since, to $1,170 in 2025.
Across 295 payments — averaging $43.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$4K
- GSK$4K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$713
- Sanofi$589
- Kaleo, Inc.$388
- plus $2K from 18 others
What the payments were for
- Consulting fees$5,10039%
- Travel & lodging$7166%
- Food & beverage$7,11355%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 34 | $3,835 |
| GSK | 59 | $3,700 |
| AstraZeneca | 89 | $1,953 |
| Regeneron Healthcare Solutions, Inc. | 29 | $713 |
| Sanofi | 19 | $589 |
| Kaleo, Inc. | 22 | $388 |
| Alk-abello, Inc | 5 | $283 |
| Amgen(2 entities) | 11 | $243 |
| Blueprint Medicines Corporation | 2 | $199 |
| Pfizer | 3 | $192 |
| Biocryst US Sales Co., LLC | 2 | $155 |
| AbbVie | 1 | $125 |
| Inspire Medical Systems, Inc. | 1 | $96 |
| Spark Therapeutics, Inc. | 1 | $92 |
| Aerin Medical Inc. | 1 | $91 |
| Grifols USA, LLC | 3 | $79 |
| Incyte Corporation | 4 | $66 |
| Lilly USA, LLC | 2 | $46 |
| Novartis | 1 | $30 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Boehringer Ingelheim | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Quidel Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pediatric allergy/immunology providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 16 | $78,704 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $37,978 |
| RyaltrisOlopatadine Hcl/Mometasone | 15 | $4,480 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 37 | $2,621 |
| Azelastine Hcl | 26 | $793 |
| Fluticasone Propionate | 52 | $548 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $421 |
| Montelukast Sodium | 15 | $380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $3,700 | $37,97858 claims |
| Hikma Pharmaceuticals USARyaltris | $28 | $4,48015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric allergy/immunology providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other pediatric allergy/immunology in Rockville
- Howard LedermanBaltimore$18K
- Robert WoodBaltimore$17K
- Anupama KewalramaniBaltimore$3K
- Julia WisniewskiBaltimore$2K
- Debra HouckBaltimore$2K
- Mary BollingerBaltimore$304
- Fernanda YoungBethesda$228
- Maria GutierrezBaltimore$132
- Richard LaytonTowson$91
- Kenneth SchuberthLutherville$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.